131 related articles for article (PubMed ID: 7517668)
41. HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase.
De Clercq E
Med Res Rev; 1993 May; 13(3):229-58. PubMed ID: 7683360
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and anti-HIV-1 activity of novel TSAO-T derivatives modified at the 2'- and 5'-positions of the sugar moiety.
Ingate S; Pérez-Pérez MJ; De Clercq E; Balzarini J; Camarasa MJ
Antiviral Res; 1995 Jun; 27(3):281-99. PubMed ID: 8540750
[TBL] [Abstract][Full Text] [Related]
43. Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strains.
Balzarini J; Baba M; De Clercq E
Antimicrob Agents Chemother; 1995 Apr; 39(4):998-1002. PubMed ID: 7540384
[TBL] [Abstract][Full Text] [Related]
44. Novel series of [ddN]-[TSAO-T] heterodimers as potential bi-functional inhibitors of HIV-1 RT. Studies in the linker and ddN region.
Velázquez S; Tuñón V; Jimeno ML; Pérez-Pérez MJ; San-Félix A; Chamorro C; Lobatón E; Esteban-Gamboa A; De Clercq E; Balzarini J; Camarasa MJ
Nucleosides Nucleotides; 1999; 18(4-5):1029-30. PubMed ID: 10432737
[TBL] [Abstract][Full Text] [Related]
45. The processivity of DNA synthesis exhibited by drug-resistant variants of human immunodeficiency virus type-1 reverse transcriptase.
Avidan O; Hizi A
Nucleic Acids Res; 1998 Apr; 26(7):1713-7. PubMed ID: 9512543
[TBL] [Abstract][Full Text] [Related]
46. Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
Balzarini J; Karlsson A; De Clercq E
Mol Pharmacol; 1993 Oct; 44(4):694-701. PubMed ID: 7694068
[TBL] [Abstract][Full Text] [Related]
47. Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis.
de Vreese K; Debyser Z; Vandamme AM; Pauwels R; Desmyter J; de Clercq E; Anné J
Virology; 1992 Jun; 188(2):900-4. PubMed ID: 1374986
[TBL] [Abstract][Full Text] [Related]
48. 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase.
Balzarini J; Pérez-Pérez MJ; San-Félix A; Schols D; Perno CF; Vandamme AM; Camarasa MJ; De Clercq E
Proc Natl Acad Sci U S A; 1992 May; 89(10):4392-6. PubMed ID: 1374900
[TBL] [Abstract][Full Text] [Related]
49. The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors.
Emini EA; Byrnes VW; Condra JH; Schleif WA; Sardana VV
Arch Virol Suppl; 1994; 9():11-7. PubMed ID: 7518271
[TBL] [Abstract][Full Text] [Related]
50. Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase.
Fujihashi T; Hara H; Sakata T; Mori K; Higuchi H; Tanaka A; Kaji H; Kaji A
Antimicrob Agents Chemother; 1995 Sep; 39(9):2000-7. PubMed ID: 8540706
[TBL] [Abstract][Full Text] [Related]
51. Regiospecific synthesis and anti-human immunodeficiency virus activity of novel 5-substituted N-alkylcarbamoyl and N,N-dialkylcarbamoyl 1,2,3-triazole-TSAO analogues.
Velázquez S; Alvarez R; Pérez C; Gago F; De Clercq E; Balzarini J; Camarasa MJ
Antivir Chem Chemother; 1998 Nov; 9(6):481-9. PubMed ID: 9865386
[TBL] [Abstract][Full Text] [Related]
52. Resistance to nucleoside analogs of selective mutants of human immunodeficiency virus type 2 reverse transcriptase.
Perach M; Rubinek T; Hizi A
J Virol; 1995 Jan; 69(1):509-12. PubMed ID: 7527086
[TBL] [Abstract][Full Text] [Related]
53. Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus.
Mao C; Sudbeck EA; Venkatachalam TK; Uckun FM
Antivir Chem Chemother; 1999 Sep; 10(5):233-40. PubMed ID: 10574178
[TBL] [Abstract][Full Text] [Related]
54. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
[TBL] [Abstract][Full Text] [Related]
55. 1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity.
Alvarez R; Velázquez S; San-Félix A; Aquaro S; De Clercq E; Perno CF; Karlsson A; Balzarini J; Camarasa MJ
J Med Chem; 1994 Nov; 37(24):4185-94. PubMed ID: 7527463
[TBL] [Abstract][Full Text] [Related]
56. Site-directed mutagenesis of HIV reverse transcriptase to probe enzyme processivity and drug binding.
Beard WA; Wilson SH
Curr Opin Biotechnol; 1994 Aug; 5(4):414-21. PubMed ID: 7520785
[TBL] [Abstract][Full Text] [Related]
57. HIV-1 drug resistance. Molecular pathogenesis and laboratory monitoring.
D'Aquila RT
Clin Lab Med; 1994 Jun; 14(2):393-422. PubMed ID: 7523021
[TBL] [Abstract][Full Text] [Related]
58. Mechanism of resistance of human immunodeficiency virus type 1 to 2',3'-dideoxyinosine.
Martin JL; Wilson JE; Haynes RL; Furman PA
Proc Natl Acad Sci U S A; 1993 Jul; 90(13):6135-9. PubMed ID: 7687061
[TBL] [Abstract][Full Text] [Related]
59. Novel series of TSAO-T derivatives. Synthesis and anti-HIV-1 activity of 4-, 5-, and 6-substituted pyrimidine analogues.
San-Félix A; Velázquez S; Pérez-Pérez MJ; Balzarini J; De Clercq E; Camarasa MJ
J Med Chem; 1994 Feb; 37(4):453-60. PubMed ID: 7509877
[TBL] [Abstract][Full Text] [Related]
60. Novel L-lyxo and 5'-deoxy-5'-modified TSAO-T analogs: synthesis and anti-HIV-1 activity.
Ingate S; De Clercq E; Balzarini J; Camarasa MJ
Antiviral Res; 1996 Nov; 32(3):149-64. PubMed ID: 8955510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
